HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,345-7,356 of 27,277
Other study type icon
CompletedNCT00999895

A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients

Official study title

A Non-interventional, Prospective, Open-label Study for the Evaluation of the Selection and Outcome of the Antipsychotic Treatment Switch in Outpatients With Schizophrenia - ETOS Study

This study has finished and is no longer accepting participants.

Multiple locations, including Pátrai
SchizophreniaObservational studyAges 18–65
Countries
Greece
Sponsor
AstraZeneca
Other study type icon
CompletedNCT02947308

A Study Examining Adolescents With Non-Suicidal Suicide prevention

Official study title

A Longitudinal Study Examining Three RDoC Constructs in Adolescents With Non-Suicidal Self-Injury

This study has finished and is no longer accepting participants.

In Minneapolis
SuicidalityObservational studyAges 12–16
Countries
United States
Sponsor
University of Minnesota
Drug study icon
CompletedNCT00844857

A Study for Assessing Treatment of Patients Ages 10-17 With Depression in bipolarity

What is this study about?

Researchers compared Olanzapine Fluoxetine Combination (OFC) and placebo, tracking side effects to assess safety in people with bipolarity type I.

This study has finished and is no longer accepting participants.

Multiple locations, including San Diego
Bipolarity, DepressionMedication studyAges 10–17
Countries
United States, Russia
Sponsor
Eli Lilly and Company
Drug study icon
CompletedNCT00520923

A Study for people with Schizophrenia

What is this study about?

Researchers compared LY2140023, placebo and Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Banfield
SchizophreniaMedication studyAges 18–65
Countries
Argentina, Austria, Croatia, + 6 others
Sponsor
Denovo Biopharma LLC
Drug study icon
CompletedNCT00471354

Atomoxetine and school performance in children with ADHD

About this title

A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine

Read the official source — NCT00471354
Official study title

Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride

This study has finished and is no longer accepting participants.

Multiple locations, including Beijing
ADHDMedication studyAges 8–11
Countries
China, South Korea, Taiwan
Sponsor
Eli Lilly and Company
Other study type icon
CompletedNCT03629951

A Study for Schizophrenia Relapse Prediction

Official study title

An Observational Study for Schizophrenia Relapse Prediction

This study has finished and is no longer accepting participants.

Multiple locations, including Ahmedabad
SchizophreniaObservational studyAges 18–50
Countries
India
Sponsor
Janssen Research & Development, LLC
Drug study icon
CompletedNCT00195780

Long-term divalproex ER safety for mania in young people ages 10–17 with bipolarity I

About this title

A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

Read the official source — NCT00195780
Official study title

An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

This study has finished and is no longer accepting participants.

Multiple locations, including San Diego
BipolarityMedication studyAges 10–17
Countries
United States
Sponsor
Abbott
Drug study icon
TerminatedNCT01127646

A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents

Official study title

Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)

This study ended early.

Multiple locations, including Arnhem
ADHDMedication studyAges 6–16
Countries
Netherlands, Spain, Sweden
Sponsor
Eli Lilly and Company
Behavioral study icon
CompletedACTRN12626000361303

A study in Malaysia comparing a one-day parent workshop and the WHO caregiver skills training eLearning module (alone or together) for families of preschool children with autism: effects on parents’ confidence and wellbeing, and children’s behaviour and autism symptoms

Official study title

A four-arm randomised controlled trial in Malaysia among caregivers of preschool children with autism comparing a one-day parent training workshop and WHO Caregiver Skills Training eLearning (alone and in combination) on parents' confidence and wellbeing, and children's behaviour and autism symptoms.

This study has finished and is no longer accepting participants.

In Malaysia
Anxiety, DepressionInterventional studyAges 30 months+
Countries
Malaysia
Sponsor
Ker Yung Chua, Sarawak General Hospital
Other study type icon
CompletedNCT05841030

A Study in people with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

Official study title

A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNRI

This study has finished and is no longer accepting participants.

Multiple locations, including Birmingham
DepressionObservational studyAges 18–74
Countries
United States, France, Canada, + 8 others
Sponsor
Janssen Research & Development, LLC
Drug study icon
UnknownNCT03642964

A Study in people with Major Depressive Disorder

Official study title

A Phase 2a Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole IR, Given With Ondansetron in Patients With Major Depressive Disorder

Current recruitment status is unconfirmed.

In Long Beach
DepressionMedication studyAges 18–65
Countries
United States
Sponsor
Chase Therapeutics Corporation
Drug study icon
CompletedNCT03854578

A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions

Official study title

A Single Dose, Randomized, Placebo Controlled Phase I Study on the Effects of BI 1358894 on Functional MRI Measurements in an Emotional Processing Paradigm in Patients With Major Depressive Disorder

This study has finished and is no longer accepting participants.

In Berlin
DepressionMedication studyAges 18–45
Countries
Germany
Sponsor
Boehringer Ingelheim

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.